4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-22-048166
Chief Executive Officer sold 25,000 shares at an average $66.84 ($1,671,084)
- Chief Executive Officer acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2022-08-29 | Option exercise | +25,000 | $16.21 | $405,250 | 315,279 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-08-29 | Sale | −4,073 | $66.14 | $269,390 | 311,206 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-08-29 | Sale | −20,764 | $66.98 | $1,390,669 | 290,442 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-08-29 | Sale | −163 | $67.64 | $11,025 | 290,279 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2022-08-29 | Option exercise · Stock Option (Right to Buy) | −25,000 | 58,333 | D | ||
| Open-market sales · 25,000 sh · avg $66.84 · $1,671,084 | |||||||
Loading xslF345X03/doc4.xml…